Financial Perspectives’s IRulya Therapeutics Inc. Common Stock IRLA Stock Holding History

Financial Perspectives’s Portfolio IRLA Stock Details IRLA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q4	–	Sell	-2	Closed	-$241	–	732
2024 Q3	$241	Hold	2	–	–	﹤0.01%	654
2024 Q2	$233	Hold	2	–	–	﹤0.01%	652
2024 Q1	$329	Hold	2	–	–	﹤0.01%	637
2023 Q4	$326	Hold	2	–	–	﹤0.01%	664
2023 Q3	$347	Hold	2	–	–	﹤0.01%	670
2023 Q2	$467	Hold	2	–	–	﹤0.01%	647
2023 Q1	$484	Hold	2	–	–	﹤0.01%	646
2022 Q4	$198	Hold	2	–	–	﹤0.01%	663
2022 Q3	$412	Hold	2	–	–	﹤0.01%	660
2022 Q2	$688	Hold	2	–	–	﹤0.01%	642
2022 Q1	$1.92K	Hold	2	–	–	﹤0.01%	613
2021 Q4	$3.91K	Buy	+2	New	+$12.2K	﹤0.01%	539

Other funds holding IRLA

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

ECG

EPIQ Capital Group San Francisco, California $383M AUM 46.87% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

HighTower Advisors Chicago, Illinois $104B AUM 28.3% 1-Year Est. Return

Shay Capital New York $1.56B AUM 46.17% 1-Year Est. Return

Alphabet Inc Mountain View, California $99.1B AUM 124.46% 1-Year Est. Return

ACM

ADAR1 Capital Management Austin, Texas $2.19B AUM 374.99% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

Financial Perspectives's IRLA Position: Q4 2024 in Review

Financial Perspectives sold out of IRulya Therapeutics Inc. Common Stock (IRLA) in Q4 2024, closing a stake of 2 shares — an estimated $241 sold.

Financial Perspectives first reported a position in IRLA in Q4 2021 and held it in 12 quarters. The position peaked at $3.91K in Q4 2021. 33 funds tracked by Wall St. Rank hold IRLA as of Q4 2024.

Financial Perspectives reported no remaining IRulya Therapeutics Inc. Common Stock position as of Q4 2024 after selling out during the quarter.
Financial Perspectives sold 2 IRulya Therapeutics Inc. Common Stock shares in Q4 2024, an estimated $241.
Financial Perspectives first reported a position in IRulya Therapeutics Inc. Common Stock in Q4 2021 and held it in 12 quarters.
Financial Perspectives's IRulya Therapeutics Inc. Common Stock position peaked at $3.91K in Q4 2021.
33 funds tracked by Wall St. Rank held IRulya Therapeutics Inc. Common Stock as of Q4 2024.

Based on Financial Perspectives's 13F filing for Q4 2024, filed 3 Feb 2025.